Journal article
The COMPASS Trial
Abstract
BACKGROUND: Rivaroxaban 2.5 mg twice daily plus acetylsalicylic acid (aspirin; ASA) 100 mg reduced the risk of cardiovascular events as compared with ASA monotherapy in the COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies) but increased the risk of major bleedings. Analysis of net clinical benefit (NCB) is of key clinical relevance and represents an integrated measure of overall patient outcome.
METHODS: The …
Authors
Steffel J; Eikelboom JW; Anand SS; Shestakovska O; Yusuf S; Fox KAA
Journal
Circulation, Vol. 142, No. 1, pp. 40–48
Publisher
Wolters Kluwer
Publication Date
July 7, 2020
DOI
10.1161/circulationaha.120.046048
ISSN
0009-7322